Novartis AG’s recently acquired monoclonal antibody SEG101 showed a statistically significant reduction in sickle cell pain crises at the antibody’s highest dose in the Phase II SUSTAIN clinical trial, which one analyst said could generate $1bn or more in annual revenue given the high unmet need for the hereditary disease.
The company has not indicated when it will begin a Phase III program for SEG101 (crizanlizumab; formerly SelG1), which inhibits p-selectin, but Novartis told Scrip that it “will continue the...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?